HAE Haemonetics Corporation
Company Analysis
Latest News
🔴 Haemonetics is trading 5.4% down today after a cut to full-year margin expansion guidance
Haemonetics is trading 5.39% lower at $117.42 as lower full-year operating-margin expansion guidance is the clearest company-specific explanation for the...
🔴 Haemonetics is trading 4.36% down today after lowering its full-year margin expansion outlook
Haemonetics is trading at $121.86, down 4.36%, after lowering its full-year adjusted operating-margin expansion outlook to 0–50 basis points from 50–100 basis...
Haemonetics beats second quarter 2027 expectations and raises full-year organic revenue guidance
Haemonetics reported a strong second quarter of fiscal 2027, beating consensus estimates on both revenue and earnings. Performance was anchored by double-digit...
🟢 Haemonetics is trading 4.08% up today amid a broad U.S. market rally
Haemonetics is trading 4.08% up at $124.32 as U.S. markets rally. - Major indexes were up more than 2% around this time. - No clear company-specific...
Haemonetics Corporation Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
Analysts expect Haemonetics to report consensus revenue of $345.15 million and adjusted EPS of $1.29, with the stock currently trading near $120.14, slightly...
🟢 Haemonetics is trading 4.7% up in after-hours trading after CSL's planned rollout to U.S. plasma centers and Mizuho's price target hike
Haemonetics is trading at $124.27, up 4.67% in after-hours trading. This follows CSL's October 8 update on a planned rollout of Haemonetics devices across all...
CSL's Bet on Haemonetics Plasma Gear Could Revive a $117 Million Revenue Stream — But Can Investors Trust a Deal With No Minimums?
Shares of Haemonetics surged +12.4% to $114.33 Thursday after CSL, one of the world's largest plasma collectors, said it expects to equip all of its U.S....
🟢 Haemonetics is trading 12.41% up after CSL set 2027 U.S. NexSys rollout target
Haemonetics is trading at $114.33, up 12.41%, after CSL said it expects to complete rollout of NexSys PCS devices and related disposables across all current...
Haemonetics provides timeline for CSL Plasma U.S. device rollout by year-end 2027
Haemonetics provided an update on its non-exclusive supply agreement with CSL Plasma, announcing that CSL expects to complete the rollout of Haemonetics'...
🟢 Haemonetics is trading 12.2% up in pre-market — catalyst unconfirmed
Haemonetics is trading at $114.12, up 12.2%, with the reason for the gain unconfirmed. - Shares compare with the October 7 close of $101.71. - Available news...
🟢 Haemonetics is trading 9.13% up in pre-market — catalyst remains unconfirmed
Haemonetics is trading 9.13% up in pre-market at $110.99 on October 8; the reason for the move remains unconfirmed. - The price compares with the October 7...
🔴 Haemonetics is trading 47.5% down in after-hours trading — no reliable company-specific catalyst identified
Haemonetics is trading at $57.01, down 47.50% in after-hours trading, with no reliable company-specific announcement, earnings release, or regulatory event...
🟢 Haemonetics is trading 4.3% up today as investors seek defensive exposure
Haemonetics is trading 4.3% up at $107.06, outperforming a broadly weaker market on September 14, 2026, in a primarily sector-driven move as investors seek...
John Rogers' Ariel Investments Discloses New $155M Haemonetics Stake
Ariel Investments, the firm founded by prominent value investor John Rogers, has initiated a new position in Haemonetics Corp. (HAE), a global medical...
🟢 Haemonetics is trading 6.2% up in after-hours trading after CSL Plasma supply agreement
Haemonetics is trading 6.2% up at $114.90 after investors continued reacting to its non-exclusive CSL Plasma supply agreement. - The agreement allows CSL to...
🟢 Haemonetics is trading 6.2% up in pre-market after CSL Plasma returns to NexSys platform
Haemonetics is trading 6.18% up at $111.12 after investors continued reacting to its non-exclusive supply agreement with CSL Plasma. - The agreement allows...
🟢 Haemonetics is trading 16.2% up today after disclosing U.S. supply agreement with CSL Plasma
Haemonetics is trading 16.2% up at $104.84 after disclosing an August 14, 2026 non-exclusive U.S. supply agreement with CSL Plasma. - CSL Plasma may use...
Haemonetics Wins Back CSL Plasma After a Bitter 2021 Divorce — But Can a Non-Exclusive Deal Justify a 10% Rally?
Shares of Haemonetics surged 10.2% to $99.50 on Tuesday after the company disclosed it had signed a new U.S. supply agreement with CSL Plasma, the world's...
🟢 Haemonetics is trading 10.22% up in pre-market after disclosing CSL Plasma supply agreement
Haemonetics is trading 10.22% up at $99.50 after disclosing a non-exclusive U.S. supply agreement with CSL Plasma on August 18, 2026. - The agreement covers...
🟢 Haemonetics is trading 6.4% up in pre-market; no clear immediate catalyst identified
Haemonetics is trading at $96.06 (+6.41%) after no clearly identifiable company-specific announcement on August 18, 2026. - The latest major catalyst was the...